Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

por Thongprasert, Sumitra, Geater, Sarayut L, Clement, Dana, Abdelaziz, Amr, Reyes-Igama, Jasmin, Jovanovic, Dragana, Alexandru, Aurelia, Schenker, Michael, Sriuranpong, Virote, Serwatowski, Piotr, Suresh, Sheethal, Cseh, Agnieszka, Gaafar, Rabab
Publicado 2019

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Stud...

por Trukhin, Dmytro, Poddubskaya, Elena, Andric, Zoran, Makharadze, Tamta, Bellala, Ravi Shankar, Charoentum, Chaiyut, Yañez Ruiz, Eduardo P., Fulop, Andrea, Hyder Ali, Irfhan Ali, Syrigos, Kostas, Katgi, Nuran, Lopez Chuken, Yamil Alonso, Rumyana, Ilieva, Reyes-Igama, Jasmin, Costamilan, Rita de Cassia, Del Campo García, Ana, Florez, Amalia, Paravisini, Alexandra, Millan, Susana
Publicado 2021